Arcturus Therapeutics Holdings Inc

ARCT is entrenched in a Stage 4 decline with sequential lower highs and lows and persistent selling pressure. Price remains below down-sloping 9/21/50 EMAs and the 50/200 DMAs, and recent tests into the EMA band have been rejected. Oversold conditions show no exhaustion, reinforcing bearish momentum. With no mean-reversion eligibility and a Speculative strategy focus on clear structural asymmetry, execution now into the EMA resistance zone aligns with optimal risk-reward on the downside.

• ↑Holds $191.5 M cash runway into Q4 2028, limiting dilution.
• ↑ARCT-032 Phase III decision expected by end-Q4 2026.
• ↓Q2 revenue fell to $3.0 M; net loss of $23.8 M (−$0.84/share).